Quicker Psychedelic Drugs Offer Investors a Better Trip

Psychedelic drug companies face a renewed but fragile investor outlook, and shorter-acting therapies are framed as a key path to commercial viability. The column points to progress in trial data and a more open political tone from senior Trump administration officials around using psychedelics to address mental health conditions. It also argues that long supervised dosing windows reduce business appeal because patients may need oversight for roughly 6 to 12 hours. By focusing on faster onset and shorter duration compounds, the piece suggests the sector can reduce operational complexity, improve patient experience, and support a return to stronger capital flows for psychedelics firms.